Hepatitis CNCT04618679
Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.
An observational study of Hepatitis C, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Hepatitis C
- How many people
- 100 participants
- Where
- 1 siteTaiwan
- Study dates
- 2 Nov 2020to 30 Jun 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Outpatient department of hospital
Adults (older than 20-year-old) with HCV infection and agree to accept 18F-FDOPA PET examination.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
National Taiwan University Hospital
Douliu, Yunlin County, 640
Chia-Ju Liu, MD, 886972655524, Y05955@ms1.ylh.gov.tw
About this study
-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.
Read the detailed description
Parkinson's disease (PD) is the second-most neurodegenerative disease in Taiwan. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The estimated incidence of PD ranging from 10-18 per 100,000 person-years with a tread of increasing number over past decades. Although the exact mechanisms of PD have not yet fully clear, many pathological process have shown to be involved in the pathogenesis like abnormal alpha-synuclein, activation of microglia and astrocyte, mitochondrial dysfunction, oxidative stress, and so on.
Several characteristics have been considered to increase the risk of having PD. Epidemiologic studies have suggested that patients with HCV infection might have higher risk of PD. It is common that patients with chronic HCV infection manifest with central nervous system manifestations, such as depression, fatigue, and cognitive dysfunction. A previous epidemiologic study in Taiwan with a total of 62,276 subjects showed that there is significant correlation between PD and hepatitic C virus (HCV) infection. In the study, the crude odds ratio for having PD was 1.94 for HCV patients.
HCV is positive-stranded RNA virus of Flaviviridae family. Flaviviridae family has many viruses demonstrating neurotropic character and may be associated with encephalopathy. Decreased monoamine transporter binding activity had also been found in HCV infected patients who had symptoms of chronic fatigue and cognitive impairment. HCV can cross blood-brain barrier and has the ability to replicate in the central nervous system. Animal study has shown that HCV infection may up-regulate the inflammatory cytokines, such as sICAM-1, LIX, and RANTES, in the rat midbrain neuron-glia coculture and induced dopaminergic neuronal toxicity. The elevation of choline/creatine ratio on proton magnetic-resonance spectroscopy is also indicative of inflammatory status of brain in patients with chronic HCV infection. it is possible that the direct infection of HCV into the brain induce inflammatory status by microglia/macrophages and contribute to subsequent neurodegeneration. Chronic HCV infection is also associated with systemic cytokine activation including interferon-α and tumor necrosis factor α, which may also affect the neuronal function. It has been reported that the viral eradication on the patients infected by HCV had change of neurocognitive function.
6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) is an analog of L-dihydroxyphenylalanine (L-DOPA), which is the precursor of dopamine. L-DOPA is carried into the brain through neutral amino acid transport system and converted to domapine by aromatic L-amino acid decarboxylase (AADC) in dopaminergic neurons. Use 18F-FDOPA as a tracer of positron emission tomography (PET) imaging, the dopamine synthesis rate and presynaptic dopaminergic neuronal function can be reflected by the uptake of 18F-FDOPA in dopaminergic neurons. The decline of 18F-FDOPA is indicative of dopaminergic neurons dysfunction and can be used as imaging marker of the severity of PD. The posterior putamen receives the dopaminergic projections from the ventrolateral part of the substantia nigra and is affected earliest in the disease course of PD. 18F-FDOPA has been shown its capacity in differentiating early PD and healthy controls in previous study with lower metabolism in the dorsal putamen even in the early course of PD.
In this project, 18F-FDOPA PET is used as an imaging marker of striatal dopaminergic dysfunction in patients with HCV infection. We will try to detect the subclinical and preclinical stages of parkinsonism for these patients.
- Conditions
- Hepatitis C
- Keywords
- HBV,Parkinson's disease,18F-FDOPA PET
- Medical subject headings
- Hepatitis C
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 18F-FDOPA PET | Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.
To evaluate the uptake of 18F-FDOPA in the basal ganglia of patients with HCV infection. Use 18F-FDOPA PET as an imaging marker to diagnosis preclincal Parkinson's disease in patients with HCV infection.
Measured: 2 weeks
Secondary outcomes (1)
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.
To compare the findings of 18F-FDOPA PET with the disease status of HCV infection and investigate possible correlation between the severity of Parkinson's disease and HCV infection status.
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2020
- Study start2 Nov 2020 (estimated)
- Primary completion30 Jun 2021 (estimated)
- Study completion30 Jun 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatitis CStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chia-Ju v Liu, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04618679
- Sponsor's protocol ID
- 201912133MIND
- Status last verified
- Oct 2020
- First submitted
- 1 Nov 2020
- Last updated
- 6 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.
- ClinicalTrials.gov ID
- NCT04618679
- Acronym / sponsor ID
- 201912133MIND
- Conditions
- Hepatitis C
- Keywords
- HBV,Parkinson's disease,18F-FDOPA PET
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 2 Nov 2020 (estimated)
- Primary completion
- 30 Jun 2021 (estimated)
- Study completion
- 30 Jun 2021 (estimated)
- First posted
- 6 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.
Detailed description
Parkinson's disease (PD) is the second-most neurodegenerative disease in Taiwan. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The estimated incidence of PD ranging from 10-18 per 100,000 person-years with a tread of increasing number over past decades. Although the exact mechanisms of PD have not yet fully clear, many pathological process have shown to be involved in the pathogenesis like abnormal alpha-synuclein, activation of microglia and astrocyte, mitochondrial dysfunction, oxidative stress, and so on.
Several characteristics have been considered to increase the risk of having PD. Epidemiologic studies have suggested that patients with HCV infection might have higher risk of PD. It is common that patients with chronic HCV infection manifest with central nervous system manifestations, such as depression, fatigue, and cognitive dysfunction. A previous epidemiologic study in Taiwan with a total of 62,276 subjects showed that there is significant correlation between PD and hepatitic C virus (HCV) infection. In the study, the crude odds ratio for having PD was 1.94 for HCV patients.
HCV is positive-stranded RNA virus of Flaviviridae family. Flaviviridae family has many viruses demonstrating neurotropic character and may be associated with encephalopathy. Decreased monoamine transporter binding activity had also been found in HCV infected patients who had symptoms of chronic fatigue and cognitive impairment. HCV can cross blood-brain barrier and has the ability to replicate in the central nervous system. Animal study has shown that HCV infection may up-regulate the inflammatory cytokines, such as sICAM-1, LIX, and RANTES, in the rat midbrain neuron-glia coculture and induced dopaminergic neuronal toxicity. The elevation of choline/creatine ratio on proton magnetic-resonance spectroscopy is also indicative of inflammatory status of brain in patients with chronic HCV infection. it is possible that the direct infection of HCV into the brain induce inflammatory status by microglia/macrophages and contribute to subsequent neurodegeneration. Chronic HCV infection is also associated with systemic cytokine activation including interferon-α and tumor necrosis factor α, which may also affect the neuronal function. It has been reported that the viral eradication on the patients infected by HCV had change of neurocognitive function.
6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) is an analog of L-dihydroxyphenylalanine (L-DOPA), which is the precursor of dopamine. L-DOPA is carried into the brain through neutral amino acid transport system and converted to domapine by aromatic L-amino acid decarboxylase (AADC) in dopaminergic neurons. Use 18F-FDOPA as a tracer of positron emission tomography (PET) imaging, the dopamine synthesis rate and presynaptic dopaminergic neuronal function can be reflected by the uptake of 18F-FDOPA in dopaminergic neurons. The decline of 18F-FDOPA is indicative of dopaminergic neurons dysfunction and can be used as imaging marker of the severity of PD. The posterior putamen receives the dopaminergic projections from the ventrolateral part of the substantia nigra and is affected earliest in the disease course of PD. 18F-FDOPA has been shown its capacity in differentiating early PD and healthy controls in previous study with lower metabolism in the dorsal putamen even in the early course of PD.
In this project, 18F-FDOPA PET is used as an imaging marker of striatal dopaminergic dysfunction in patients with HCV infection. We will try to detect the subclinical and preclinical stages of parkinsonism for these patients.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 18F-FDOPA PET | – | –Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Outpatient department of hospital
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.
Time frame: 2 weeks
To evaluate the uptake of 18F-FDOPA in the basal ganglia of patients with HCV infection. Use 18F-FDOPA PET as an imaging marker to diagnosis preclincal Parkinson's disease in patients with HCV infection.
1 secondary outcome
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.
Time frame: 2 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2020.
Related trials for Hepatitis C
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Not yet recruitingObservational study
Elimination of Hepatitis C Virus Among Users of Substances
Hepatitis C in Substance Users
Not yet recruiting
Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use
HCV Infection
Not yet recruiting
Study to Evaluate the Performance of the INSTI® HCV Antibody Test for Point-of-Care Use in Individuals at Risk for HCV Infection or Presenting With Signs or Symptoms of HCV Infection
HCV Infection
Active, not recruitingPhase 4
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Diabetes Mellitus, Hepatitis C, Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chia-Ju v Liu, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatitis C, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chia-Ju Liu, MD (886972655524, Y05955@ms1.ylh.gov.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease. (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2020.